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Abstract
Background: HIV prevention research has been fraught with ethical concerns since its inception.
These concerns were highlighted during HIV vaccine research and have been elaborated in
microbicide research. A host of unique ethical concerns pervade the microbicide research process
from trial design to post-trial microbicide availability. Given the urgency of research and
development in the face of the devastating HIV pandemic, these ethical concerns represent an
enormous challenge for investigators, sponsors and Research Ethics Committees (RECs) both
locally and internationally.
Discussion: Ethical concerns relating to safety in microbicide research are a major international
concern. However, in the urgency to develop a medically efficacious microbicide, some of these
concerns may not have been anticipated. In the risk-benefit assessment of research protocols, both
medical and psycho-social risk must be considered. In this paper four main areas that have a
potential for medical and/or psycho-social harm are examined. Male partner involvement is
controversial in the setting of covert use of microbicides. However, given the long-term exposure
of men to experimental products, this may be methodologically, ethically and legally important.
Covert use of microbicides may impact negatively on relationship dynamics leading to psychosocial
harm to varying extents. The unexpectedly high rates of pregnancy during clinical trials raise
important methodological and ethical concerns. Enrollment of adolescents without parental
consent generates ethical and legal concerns that must be carefully considered by RECs and trial
sites. Finally, paradoxical outcomes in recent trials internationally have advanced the debate on the
nature of informed consent and responsibility of researchers to participants who become HIV
positive during or after trials.
Summary: Phase 3 microbicide trials are an undisputed research and ethical priority in developing
countries. However, such trials must be conducted with attention to both methodological and
ethical detail. It is imperative that guidelines are formulated to ensure that high ethical standards
are maintained despite the scientific urgency of microbicide development. Given the controversy
raised by emergent ethical issues during the course of microbicide development, it is important that
international consensus is reached amongst the various ethics and regulatory agencies in developing
and developed countries alike.
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In 1997, international debate was prompted by trials
designed to prevent the vertical transmission of HIV from
pregnant women to their babies [1]. This debate was
advanced when HIV vaccine trials were in the planning
phases and many ethical concerns were recognized [2,3].
International and national deliberation ensued and cul-
minated in the development of international guidelines
[4]. Microbicide research had an unfortunate debut with
early trials paradoxically demonstrating an increased risk
of contracting HIV – an outcome clearly antithetical to the
objectives of such preventive research [5,6]. More recently,
similar results have emerged resulting in the premature
closure of the cellulose sulphate trials at five developing
country sites internationally [7]. However, a wide range of
microbicide  gels are in various phases of clinical trial test-
ing necessitating on going reflection on the ethics of
microbicide research internationally [8-12].
Unique ethical concerns pervade all aspects of the micro-
bicide research process. Unlike HIV vaccine research,
microbicide trials involve repeated exposure of both sex-
ual partners to an experimental chemical product. If the
product is proven to be efficacious, exposure will most
likely continue on a long term basis. As such, exposure to
partners and consent to such exposure is important. Dur-
ing the course of trials unintended pregnancy may occur,
especially in trials where long term follow-up is being
assessed. Safety of these products during pregnancy must
be established. Adolescents, as a group, stand to benefit
from the availability of an effective microbicide gel yet
testing the products on them is fraught with ethical con-
cerns. Due to the potential of microbicides to result in
vaginal ulceration either as an adverse effect in normal
dosage or due to overuse as self application is involved,
the risk of developing HIV infection may increase rather
than decrease. These concerns represent an enormous
challenge for the research community and regulatory and
ethics oversight agencies locally and internationally.
Most microbicide research is conducted by developed
sponsor countries in developing host countries where the
burden of disease due to HIV/AIDS is greatest. The Coun-
cil for International Organisations of Medical Sciences
(CIOMS) 2002 guideline mandates that dual review of
research is conducted on all international collaborative
research studies [13]. As such, the ethical concerns relating
to safety are a major concern for regulatory agencies in
South Africa (SA) and other developing host countries as
well as for developed sponsor country Institutional
Review Boards (IRBs) and investigators.
While the scientific aspects of microbicide research have
been widely published [5-12,14], and extensive research
relating to acceptability of microbicides and partner
involvement has been conducted [15-24], there is a pau-
city of literature relating to the ethical deliberation around
microbicide research. Ethical concerns published to date
relate to treatment of HIV seroconverters during and after
trials, use of placebo and condom only arms in trial
design, standards of care and informed consent [25-27].
This paper addresses four main safety issues related to
microbicide research where methodological and ethical
concerns exist.
Discussion
Safety in microbicide trials
While ethical considerations range from conceptual issues
in trial design through to post trial availability of effica-
cious products and post marketing surveillance, only the
ethical issues relating to safety will be discussed in this
paper. These issues include both medical and psychoso-
cial harms that may result from microbicide use. Medical
harms refer to physical adverse events that may result
from the use of an experimental microbicide gel. Psycho-
social harms refer to the impact of covert use of these
products on relationship and family dynamics especially
in developing country contexts where women are disem-
powered. Male partner consent remains controversial yet
requires resolution to reduce both psychosocial harms as
well as medical harms that could result from potential
penile toxicity. Involvement of male partners becomes
imperative if the inclusion of pregnant women in micro-
bicide research becomes standard practice. This is a tangi-
ble possibility given the high pregnancy rates emerging in
many microbicide trials. Enrollment of adolescents with-
out parental consent in SA is extremely contentious and
has the potential for medical and psychosocial harm to
this group of vulnerable participants. An important end-
point of any microbicide clinical trial is HIV seroconver-
sion. The expectation is that such seroconversion will be
lower in the experimental microbicide gel group than the
placebo group. When HIV seroconversion is higher in the
experimental group, this is a cause for concern and raises
questions about risk to participants and their partners,
product safety, informed consent, return of results to
research communities, as well as care of HIV seroconver-
tors. These ethical concerns will be elaborated below.
RECs and risk-benefit analysis
RECs are charged with the weighty responsibility of partic-
ipant protection in research. Central to this function is an
adequate assessment of risk imposed on participants by a
research study or investigational agent in relation to ben-
efits accrued by participation. Of the wide range of prod-
ucts under experimentation at present, each has a different
chemical composition. Risk in terms of toxicity varies
from mild local symptoms to systemic absorption and
risk to partners. The ethical concerns outlined in thisPage 2 of 7
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investigational microbicides in clinical trial development.
Most data to date indicates a range of local vaginal side-
effects. While this may sound innocuous, some adverse
events of this nature have the potential for serious risk.
This was demonstrated in the first microbicide trial of
Nonoxynol 9 where vaginal ulceration that resulted from
product use increased transmission of HIV requiring the
studies to be terminated [5,6]. More recently, the prema-
ture closure of the cellulose sulphate trials was based on
an unfavourable risk-benefit ratio resulting in a higher
rate of HIV seroconversion in the treatment arm [7]. The
first phase 1 study of an antiretroviral microbicide gel
indicated that most women in the trial (92%) experienced
at least one mild adverse event – these included vaginal
pruritis, vaginal bruising related to applicator use, vaginal
discharge, amongst others. Only one participant experi-
enced a serious adverse event. Of note is the systemic
absorption of the drug demonstrated in 14 out of 25
women. As a safety trial on a small group of sexually absti-
nent women and sexually active couples, over a 2 week
period this trial provides important safety data for short
term use of the product [14]. Long term studies will need
to elucidate safety issues with chronic use. Of interest in
this study is the inclusion of male partners of sexually
active women. However, there is no data included on
adverse events in males exposed to the gel neither is there
a statement indicating that no adverse events were experi-
enced by male participants. This is an important consider-
ation for RECs and regulatory agencies who need to
deliberate on the inclusion of male partners in phase 3 tri-
als as well as the need to obtain agreement/consent from
male partners in addition to consenting women on such
trials. On the whole, there is a paucity of published infor-
mation relating to effects of microbicides on males.
Male partners – agreement/consent
The philosophy underlying microbicide trials relates to
the empowerment of women to protect themselves from
a life-threatening disease in settings where they are unable
to negotiate safe sex. Given this rationale, it seems almost
antithetical to consider obtaining agreement or consent
from male partners. However, in clinical trials where both
partners are exposed to an experimental vaginal gel, part-
ner agreement/consent and couple consent as opposed to
female participant consent only is an important consider-
ation.
Several arguments have been advanced for excluding men
from microbicide trials. In patriarchal communities where
men are the primary decision-makers on most issues
including matters relating to sexual intercourse and inti-
macy, researchers fear that male partners will prevent
women from participating in clinical trials and from using
microbicide products. In large phase 3 trials it may be
impractical to get male partners to attend research sites
due to competing commitments related to employment.
The inclusion of men as part of phase 3 trials will signifi-
cantly increase the costs and resources required for such
trials in research studies that are poorly supported by the
pharmaceutical industry. Finally, where female partici-
pants have multiple male partners, it may be logistically
difficult to include all partners in the trial.
Equally compelling arguments can be advanced for the
inclusion of male partners in microbicide trials. Firstly,
male partners are being exposed to an investigational
agent and are exposed to physical risk. Since pre-clinical
testing of microbicides includes testing for "penile toxic-
ity", clinical testing should also involve male partners
with their consent to assess for acute and long term local
effects. Failure to do so could have legal ramifications in
the long term especially if chronic use of these investiga-
tional products is later found to be associated with penile
toxicity or if these products are found to increase risk of
HIV as has been documented in women [5-7]. In the
United States, it is an FDA requirement that any microbi-
cide with systemic activity (such as Tenofovir Gel) will
require investigation for penile absorption in male part-
ners [28]. The World Health Organisation (WHO) guid-
ance on reproductive health research and partner
involvement favours respect for individual participant
autonomy in all situations. However, partner agreement
should be made a condition of recruitment only if the
research will "so immediately affect the partner as to make
him or her comparable to a subject of the research". This
is applicable to microbicide gels in general especially
those with systemic absorption. As such, partner notifica-
tion is justified only when there is physical risk to the part-
ner such as infection or infertility according to the WHO
guidelines [29]. These guidelines do not take into account
local physical side-effects, psycho-social and emotional
harm that may impact on partners exposed to experimen-
tal products.
While microbicide development has been targeted prima-
rily at women, some acceptability studies have included
men. Several of these studies have shown male partner
interest in microbicide research [15-18]. In particular,
research from South Africa has found that 66–82% of
male partners would like to be included in microbicide
trials [16].
While microbicide development has been fuelled by the
hope that women will be empowered to protect them-
selves from their partners covertly with their own vaginal
gel, many women in developing countries actually prefer
to involve their partners [18-22]. This is often the case in
settings where autonomy is not expressed in an individu-Page 3 of 7
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hood may require couple or family consent as opposed to
individual consent. In recognition of this socio-cultural
preference in some developing countries the WHO, in its
guidance on reproductive research, makes provision for
partner agreement when required. This is, however, the
exception rather than the rule as the WHO, in general,
regards partner consent as inappropriate and as a viola-
tion of participant autonomy [29].
Where women prefer not to tell their partners, covert use
may be very difficult. Most microbicides (86% of those
being tested to date) increase lubrication [23]. Covert use
is hence not possible in populations with a preference for
dry sexual practices [24]. Furthermore, covert use could
result in mistrust and deception in developing countries
and male partners may develop antagonism towards these
products that will parallel their antagonism towards male
condoms. More importantly, covert use of microbicides
by women could result in domestic violence. There is
hence an emotional cost linked to covert use.
Finally, the testing of vaginal microbicides in pregnancy
mitigates against the exclusion of male partners in the
consenting process of clinical trials. The possibility of test-
ing microbicides during pregnancy will require reconsent-
ing women and their male partners or the father of the
potential child.
Testing microbicides during pregnancy
Most of the microbicides being tested in clinical trials are
investigational products and their safety in pregnancy has
not been established. Study participants are advised to be
on contraception during the trial, pregnancy is monitored
either monthly or 3 monthly and product use is discontin-
ued as soon as pregnancy is diagnosed. Of the numerous
microbicides in various stages of clinical testing, some are
expected to be locally absorbed only while other agents,
such as Tenofovir gel, have already shown evidence of sys-
temic absorption [14].
During the conduct of microbicide trials in developing
countries, it has become evident that pregnancy rates are
much higher than anticipated. In the Cellulose Sulfate
study there have been 50 pregnancies per hundred person
years in Lagos and 21 pregnancies per 100 person years in
Port Harcourt. Similar high pregnancy rates are quoted for
the Savvy trials in Nigeria and Ghana [30-34]. These high
pregnancy rates could impact on participant retention and
the power of the study to demonstrate an effect as more
women who become pregnant are taken off study prod-
uct.
Several factors may account for the high pregnancy rates.
Chemical pregnancies (in which implantation occurs fol-
lowed by early miscarriage) may have been diagnosed as
a result of an increased frequency of testing on clinical tri-
als. Other factors include a lack of stringent criteria for
contraceptive use and consequently use of unreliable con-
traceptive methods, inadequate counseling of participants
during the informed consent process and a lack of contra-
ceptive services at trial sites. Finally, perhaps high preg-
nancy rates in this group of participants is unavoidable
given that most participants are at the peak of their repro-
ductive cycles.
During current testing of microbicides unintended expo-
sure of participants who fall pregnant has occurred. This
has been anticipated and accepted by the FDA as long as
specific animal testing is completed and is negative. These
tests indicate whether a drug has the ability to interfere
with reproductive health, fetal development and early
development. Segment 1 studies test the effect of the drug
on general fertility and reproductive performance in ani-
mals. Segment 2 studies look for evidence of teratology in
animals and segment 3 studies examine effects on perina-
tal and postnatal development. For unintended exposure
where women fall pregnant in spite of contraceptive use
and counseling, negative segment 1 and 2 testing is
required. To date, all trials in progress discontinue micro-
bicide testing on those participants who become pregnant
and where unintended exposure has occured.
Due to the high number of participants who are falling
out of trials at present, the scientific validity of microbi-
cide trials is under threat. In order to ensure trial results
that will demonstrate product efficacy, continued testing
of microbicides during pregnancy may be required. If
intended exposure is to be permitted this will entail test-
ing of the investigational product when women on trials
inadvertantly fall pregnant. In such situations, the FDA
will assess these trials on a case-by-case basis. A range of
preclinical studies will be required to support microbicide
testing in pregnancy. These include genotoxicity studies,
general toxicology studies and carcinogenicity studies.
Where segment studies are concerned, in addition to neg-
ative segment 1 and 2 studies, negative segment 3 studies
will also be required. An additional consent process will
be required, with increased safety monitoring pre and
post delivery. At delivery, it is recommended that microbi-
cides are stopped and recommenced 4–6 weeks after
delivery [28].
To date segment 3 testing has not been conducted on
microbicides. If segment 3 testing proves to be negative,
microbicides could be tested on women who become
pregnant on clinical trials and according to FDA regula-
tions, these women will need to be reconsented [28].Page 4 of 7
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trials in developing countries:
1. Informed consent is difficult to obtain from non-preg-
nant participants on less complex trials in resource
depleted settings [35-37]. Is it fair to reconsent vulnerable
women with low levels of education for use of an experi-
mental product during pregnancy? Given the complexity
of the information to be provided and the comprehension
of the risks involved, will the consent be truly informed?
2. If experimental use of substances is to continue during
pregnancy it will be imperative to inform partners. How
will this be achieved during the trial when pregnancy
occurs if partners have been excluded from the consenting
process when women were enrolled?
3. If terratogenicity is detected in pregnant women using
the experimental microbicide, termination of pregnancy
(TOP) should be an option. In countries where TOP is not
legal, how can this option be provided? In countries
where this is legal, who will provide this service – the trial
site or state health services who are already overburdened?
4. What happens when adolescents on trials fall pregnant
and continued testing is implemented? Will parental con-
sent be required for unmarried minors?
Adolescent participation – a case study from South Africa
The enrollment of adolescents in microbicide trials in SA
has been a carefully considered decision given the very
controversial guidelines in SA relating to the involvement
of children and adolescents in research. Initial guidance
for including children in research has been extrapolated
from the Child Care Act No 74 of 1983 [38] that refers to
consent for medical treatment of children. An adolescent
over the age of 14 years may consent, unaided, to medical
treatment (this includes HIV testing). However, for surgi-
cal treatment parental consent is required for adolescents
and children under the age of 18 years. Whether a similar
extrapolation will occur from the Children's Act No 38 of
2005[39] is uncertain as the Act remains silent on chil-
dren and adolescents in research. According to the new
Act, the age of consent for medical treatment and HIV test-
ing has dropped to 12 years.
For research purposes, most studies, to date, have enrolled
participants over the age of 18 years only without parental
consent. Where HIV prevention research is concerned,
Chapter 9 of the National Health Act No 61 of 2003 will
apply [40]. Most sections on research in this chapter have
been proclaimed by the State President in 2004 and were
promulgated in May 2005. Section 71, however, has not
been proclaimed as yet. This section categorises research
as therapeutic and non-therapeutic. Microbicide research
will be regarded as non-therapeutic. As such it will be nec-
essary, once section 71 is proclaimed, to obtain consent
from the adolescent, the parent/guardian and the Minister
of Health. The guideline issued by the Department of
Health in April 2005 however, categorises research on
children using the criterion of minimal risk. This would
then require the classification of microbicide research
according to a risk level. The guideline does however
encourage research amongst adolescents where needed.
Given the conflicting legal frameworks on age of consent
and research, RECs in SA handle these protocols on a case-
by-case basis.
For example, the MCC and relevant RECs in SA have
approved the participation of 16 year old girls in the clin-
ical trial of Carraguard, without parental consent. The jus-
tification for this is based on the low age of sexual debut
in SA which places young girls at high risk of contracting
HIV. In other  words, adolescents would stand to  benefit
from a preventive  intervention such as a microbicide.
Thus, the argument for including girls younger than 18
years in microbicide research without parental consent
rests on the principle of beneficence. However, a number
of procedural issues in trial design have the potential to
raise ethical concerns where adolescent participants are
involved. In 2002, when this microbicide trial was initi-
ated, the regulatory agency in SA – the Medicines Control
Council (MCC) – specified that participants be paid R150
($23) per scheduled trial visit. It was also a requirement of
the MCC that this amount be specified in the patient
information leaflet. Given the number of trial visits
required in a microbicide trial extending over a 2 year
period, it is possible for prospective adolescent partici-
pants to calculate that participation remuneration for the
trial would amount to approximately R1500 ($214). This
represents a significant inducement in poor vulnerable
communities in SA. In addition, the trial requires that pro-
spective participants are sexually active in the 3 months
preceding enrollment. The incentive of remuneration
related to participation has the potential to inadvertently
encourage sexual activity to satisfy inclusion criteria into
the trial. Another complication regarding the enrollment
of adolescents on weekdays could imply that school
attendance may be neglected and this would be problem-
atic within the schooling system. It may be particularly
problematic if the school authorities are aware that partic-
ipation in these trials is without parental consent [41].
While it is important for adolescents to be enrolled in HIV
prevention trials it is also important for RECs to establish
criteria to protect these vulnerable participants.
Paradoxical trial results
The recent closure of the cellulose sulphate trials in devel-
oping country sites globally[7] has reawakened fears sim-
ilar to those elicited by the Nonoxynol 9 trials. HigherPage 5 of 7
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unfavourable risk-benefit ratio to participants has gener-
ated sufficient concern to prematurely terminate cellulose
sulphate trials globally. In parallel with the scientific con-
cerns, a host of ethical concerns have emerged. Central to
these is the content of the consent information given to
these participants. Were participants informed that there
was a possibility of a higher than normal risk of contract-
ing HIV based on the Nonoxynol 9 trial results and if so,
did participants appreciate this risk? Have all participants
been traced and informed of their results? What impact
does this have on current and future microbicide research?
How will partners be informed that they have been placed
at risk as a result of an experimental product? What about
partners who may have seroconverted? What about cases
of HIV seroconversion where covert use of the microbi-
cide has occurred and male partners were not aware of
their exposure to the gel and to an increased risk of HIV?
These and other questions form the basis for a Depart-
ment of Health inquiry into the early closure of the South
African cellulose sulphate trial site.
The way forward
When HIV vaccine research was being planned, interna-
tional debate relating to the ethical concerns was initiated,
several publications ensued and comprehensive national
and international guidelines evolved. Microbicide
research, on the other hand, has received considerably less
attention from a regulatory and ethical oversight perspec-
tive.
It may be argued that inadequate attention has been
devoted to the role of male partners in the research proc-
ess. This is an issue that needs to be discussed and delib-
erated by RECs, especially in developing country contexts.
The role of male partners in microbicide research presents
an unparalleled opportunity for future empirical research
at trial sites.
The informed consent process is pivotal in microbicide
research. Issues related to pregnancy prevention need to
be clearly outlined in consent documents. Reliable and
safe contraceptive methods must be specified and made
available at trial sites. Given the inevitability of pregnancy
in the target population for microbicide trials, it is imper-
ative that segment 3 testing on microbicides is conducted
as soon as possible. In this way, it will be possible for
intentional testing of microbicides to occur during preg-
nancy coupled with an intensive informed consent proc-
ess involving male partners.
Adolescent enrollment is important. However, RECs must
request a plan from trial sites regarding avoidance of coer-
cion and interruption of schooling. If necessary, special
arrangements must be made for adolescents to be seen
after school or on Saturdays. Trial remuneration should
not be included in consent forms. For long term studies,
reduced remuneration should be considered and
endorsed by RECs and regulatory agencies, especially in
developing countries where small amounts of money may
be regarded as coercive in settings of participant vulnera-
bility.
The informed consent process must also be clear about
the possibility of increased risk of HIV infection given the
precedent set by Nonoxynol 9 and Cellulose Sulphate. In
the event of such an outcome, clear procedures must be in
place for tracing of participants, provision of treatment
and notification of partners.
Finally, the crisis created by the premature closure of the
cellulose sulphate trials must be handled with sensitivity.
Responsible media coverage is essential to prevent sensa-
tionalisation of microbicide research and to minimize the
negative impact on enrollment.
Summary
The complexity of microbicide research in developing
countries is augmented by a host of unique ethical con-
cerns. In the haste to develop an urgently needed microbi-
cide (which in itself is an ethical imperative), some of
these concerns, especially those related to safety have
either not been anticipated or fully explored. The develop-
ment of guidelines pertaining to the ethics of microbicide
research is important to investigators and ethics commit-
tees alike internationally. Both formative and empirical
research is required to resolve these dilemmas to ensure
participant protection without obstructing the conduct of
urgent and important HIV preventive research. Reaching
consensus on ethical oversight at an international level is
crucial.
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